Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medicardium is a healthcare company specializing in detoxification and cardiovascular wellness through its proprietary EDTA chelation products. Founded in 2000 and led by inventor Spencer Feldman, the company is best known for its Medicardium suppositories, which utilize a unique Magnesium Di-Potassium EDTA formula designed to remove heavy metals and address soft tissue calcification. Unlike traditional intravenous chelation, Medicardium's suppository-based delivery system offers a non-invasive, at-home alternative that bypasses the digestive tract for improved systemic absorption. The company's product line, marketed under the RemedyLink brand, also includes formulations for liver, kidney, and lymphatic support. Medicardium primarily serves the alternative medicine, holistic health, and chiropractic sectors, focusing on anti-aging and systemic detoxification.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medicardium.